| answer text |
<p>The following table shows estimated expenditure by the National Institute for Health
Research (NIHR) through its research programmes, research centres and units, and research
fellowships on research relating to therapies using embryonic stem cells and therapies
using stem cells from non-embryonic sources.</p><p> </p><p> </p><p> </p><p><em>£ million</em></p><p>
</p><table><tbody><tr><td><p> </p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td></tr><tr><td><p>Embryonic</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Non-embryonic</p></td><td><p>4.2</p></td><td><p>4.5</p></td><td><p>4.9</p></td><td><p>4.0</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p>Comparable data for 2010/11 are not available. Total spend
by the NIHR on these topics is higher than the figures shown because expenditure by
the NIHR Clinical Research Network (CRN) on stem cell therapies cannot be disaggregated
from total CRN expenditure.</p><p> </p><p> </p><p> </p><p>Total spend in future years
by the NIHR on these topics depends on the volume and quality of scientific activity.
The usual practice of the NIHR is not to ring-fence funds for expenditure on particular
topics: research proposals in all areas compete for the funding available. The NIHR
welcomes funding applications for research into any aspect of human health, including
stem cell therapies. These applications are subject to peer review and judged in open
competition, with awards being made on the basis of the importance of the topic to
patients and the National Health Service, value for money and scientific quality.</p><p>
</p><p> </p><p> </p><p>The Research Councils are unable to extract data related specifically
to stem cell therapies. The spend data below includes all direct stem cell research.</p><p>
</p><p> </p><p> </p><p><em>£ 000s</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td></tr><tr><td><p>
</p></td><td colspan="5"><p>Biotechnology and Biological Sciences Research Council
(BBSRC)</p></td></tr><tr><td><p>Embryonic</p></td><td><p>2,979</p></td><td><p>3,508</p></td><td><p>3,160</p></td><td><p>2,513</p></td><td><p>2,323</p></td></tr><tr><td><p>Non-embryonic</p></td><td><p>7,936</p></td><td><p>8,319</p></td><td><p>7,489</p></td><td><p>8,575</p></td><td><p>8,034</p></td></tr><tr><td><p>
</p></td><td colspan="5"><p>Engineering and Physical Sciences Research Council (EPSRC)</p></td></tr><tr><td><p>Embryonic</p></td><td><p>216</p></td><td><p>0</p></td><td><p>158</p></td><td><p>232</p></td><td><p>351</p></td></tr><tr><td><p>Non-embryonic</p></td><td><p>15,074</p></td><td><p>17,634</p></td><td><p>16,420</p></td><td><p>13,568</p></td><td><p>13,844</p></td></tr><tr><td><p>
</p></td><td colspan="5"><p>Medical Research Council (MRC)</p></td></tr><tr><td><p>Embryonic</p></td><td><p>7,639</p></td><td><p>6,886</p></td><td><p>6,190</p></td><td><p>5,189</p></td><td><p>n/a</p></td></tr><tr><td><p>Non-embryonic</p></td><td><p>17,504</p></td><td><p>19,900</p></td><td><p>19,831</p></td><td><p>22,207</p></td><td><p>n/a</p></td></tr><tr><td><p>Embryonic
and non-embryonic</p></td><td><p>12,790</p></td><td><p>12,361</p></td><td><p>17,986</p></td><td><p>27,241</p></td><td><p>n/a</p></td></tr><tr><td><p>
</p></td><td colspan="5"><p>Science and Technology Facilities Council (STFC)</p></td></tr><tr><td><p>Non-embryonic</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td><td><p>9</p></td><td><p>18</p></td></tr></tbody></table><p>
</p><p> </p><p> </p><p><em>Notes</em></p><p> </p><p>- BBSRC data in the ‘non-embryonic’
category covers research involving adult stem cells, including research relating to
foetal, cord blood and induced Pluripotent Stem cells (iPS), both adult and embryonic
stem cells, where the research is generic or where the cell type is not defined. This
category also includes the BBSRC contribution to the UK National Stem Cell Network,
Stem Cells for Safer Medicine Ltd and MRC Stem Cell Bank.</p><p> </p><p>- BBSRC figures
for 2014/15 are incomplete and include forecast spend for strategic institute programme
grants, rather than actual spend in this year.</p><p> </p><p>- BBSRC figures exclude
the ‘routine’ use of mouse embryonic stem cell lines to generate transgenic mice,
unless for the purpose of studying some aspect of stem cell biology.</p><p> </p><p>-
MRC data for 2014/15 is currently unavailable.</p><p> </p><p><em> </em></p><p> </p><p>The
Arts and Humanities Research Council (AHRC) has not invested any direct funding in
this area. However, in relation to stem cell research and legal implications the AHRC
has invested £50,000 since 2012.</p><p> </p><p> </p><p> </p><p>The Cell Therapy Catapult,
which was established in 2012, has received the following funding.</p><p> </p><p>
</p><p> </p><p><em>£ 000s</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td></tr><tr><td><p>Embryonic</p></td><td><p>0</p></td><td><p>200</p></td><td><p>0</p></td></tr><tr><td><p>Non-embryonic</p></td><td><p>4,944</p></td><td><p>16,518</p></td><td><p>12,750</p></td></tr></tbody></table><p>
</p><p><strong> </strong></p><p> </p><p>The commitment to the Cell Therapy Catapult
going forward up to 2018/19 will be £10 million per annum. This will, however, be
across all areas and has not been separated out into different cell type categories.</p><p>
</p><p> </p><p> </p><p>At Budget 2014 the Cell Therapy Catapult was allocated £34
million for the establishment of a Cell Manufacturing centre. The nature of cells
being manufactured has not been decided yet so may involve stem cells.</p><p> </p><p>
</p><p> </p><p>Innovate UK has committed the following funding.</p><p> </p><p> </p><p>
</p><p><em>£ 000s</em></p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2010/11</p></td><td><p>2011/12</p></td><td><p>2012/13</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td></tr><tr><td><p>Embryonic</p></td><td><p>674</p></td><td><p>25</p></td><td><p>120</p></td><td><p>200</p></td><td><p>90</p></td></tr><tr><td><p>Non-embryonic</p></td><td><p>2,142</p></td><td><p>2,589</p></td><td><p>199</p></td><td><p>3,339</p></td><td><p>3,526</p></td></tr></tbody></table><p>
</p><p><strong> </strong></p><p> </p><p>Funding to Innovate UK for future years will
be subject to the spending review.</p><p> </p><p> </p><p> </p>
|
|
